Description
The abstract establishes that TREM2 genetic variants greatly increase AD risk, but the specific molecular pathways linking these variants to disease pathogenesis remain unclear. Understanding these mechanisms is critical for developing targeted therapeutics.
Gap type: unexplained_observation Source paper: TREM2, Microglia, and Neurodegenerative Diseases. (2017, Trends in molecular medicine, PMID:28442216)
Resolution criteria
Resolution requires: (1) Humanized TREM2 variant (R47H, T96K) knock-in mouse models show measurable deficits in at least two microglial functions compared to wild-type TREM2 at baseline: phagocytosis (pHrodo bead clearance >=30% reduction), lipid metabolism (lipid droplet accumulation >=2-fold by BODIPY staining), or survival signaling (CSF1R/AKT phosphorylation >=40% reduction); (2) Mechanism of increased AD risk: TREM2 R47H microglia in 5xFAD background show >=25% greater amyloid plaque load, >=20% reduced plaque-associated microglial recruitment (IBA1+ contact), or accelerated tau spread vs. TREM2-WT x 5xFAD, establishing functional consequence; (3) Therapeutic rescue: TREM2 agonist antibody (anti-TREM2 agonist or TREM2-Fc fusion) restores >=60% of phagocytic deficit in TREM2 R47H iPSC-derived microglia in vitro. Genetic association data without functional cellular or animal model validation is insufficient.
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:27.997493+00:00”, “resolution_summary”: “Resolved by hypothesis h-44b1c9d415: TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer’s Disease. Supporting evidence includes debate sess_SDA-2026-04-07-gap-pubmed-20260406-062207-e4ce5cf0_task_9aae8fc5.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-44b1c9d415”, “title”: “TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer’s Disease”, “score”: 0.234, “reason”: “5 token overlaps; entity overlap: trem2”, “analysis_id”: “legacy-pre-pipeline-import-v1”, “target_gene”: “TREM2”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.827427, “confidence_score”: 0.88, “status”: “proposed”, “pubmed_evidence_ids”: [“26741508”, “28165511”, “29196612”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062207-e4ce5cf0_task_9aae8fc5”, “title”: “The abstract mentions that pathological seeds have different characteristics and conformations, but the underlying molecular mechanisms that generate this diversity remain unclear. Understanding these mechanisms is critical for developing targeted therapeutic interventions.\n\nGap type: unexplained_observation\nSource paper: Protein transmission in neurodegenerative disease. (2020, Nat Rev Neurol, PMID:32203399)”, “score”: 0.593, “reason”: “13 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062207-e4ce5cf0”, “quality_score”: 0.65, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-041445-ce0abc1e_task_73907230”, “title”: “The abstract states that AQP4 ‘is part of the pathogenesis’ of CNS disorders and shows ‘notable variability’ in these conditions, but the precise causal mechanisms linking AQP4 alterations to disease development remain unexplained. Understanding these mechanisms is critical for developing AQP4-targeted therapeutics.\n\nGap type: unexplained_observation\nSource paper: Aquaporin-4 in glymphatic system, and its implication for central nervous system disorders. (2023, Neurobiol Dis, PMID:36796590)”, “score”: 0.563, “reason”: “14 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-041445-ce0abc1e”, “quality_score”: 0.757, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-06-gap-pubmed-20260406-062118-e3613755_task_9aae8fc5”, “title”: “The study shows SPP1 from perivascular cells drives microglial synaptic engulfment, but the specific receptors, signaling pathways, and molecular cascades linking SPP1 to phagocytic gene expression remain undefined. Understanding this mechanism is critical for developing targeted therapeutics that could modulate pathological synaptic loss.\n\nGap type: unexplained_observation\nSource paper: Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer’s disease. (2023, Nat Neurosci, PMID:36747024)”, “score”: 0.556, “reason”: “13 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-06-gap-pubmed-20260406-062118-e3613755”, “quality_score”: 0.704, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260411-072446-a32fa49c”, “title”: “The abstract shows TYROBP deficiency is neuroprotective despite being required for TREM2, CD33, and CR3 function - receptors associated with AD risk. This counterintuitive finding challenges current understanding of how these immune receptors contribute to AD pathogenesis.\n\nGap type: contradiction\nSource paper: Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer’s pathology. (None, None, PMID:28612290)”, “score”: 0.546, “reason”: “9 token overlaps; entity overlap: pmid, trem2”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260411-072446-a32fa49c”, “quality_score”: 0.56, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-080155-ea072afc”, “title”: “The abstract shows that Gal3 binding to pTau greatly enhances tau fibrillation, but the specific molecular interactions and structural changes driving this enhancement are not explained. Understanding this mechanism is critical for developing targeted therapeutics that could disrupt this pathogenic interaction.\n\nGap type: unexplained_observation\nSource paper: Galectin-3 aggravates microglial activation and tau transmission in tauopathy. (2024, The Journal of clinical investigation, PMID:37988169”, “score”: 0.537, “reason”: “13 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-080155-ea072afc”, “quality_score”: 0.92, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}